What happens when mega pharmaceutical companies get their new grip around one of the oldest asthma medications that many rely on for daily use? Based on historical data, it appears that one of the first action items is to exponentially increase the price of the same medication without any actual advancements of any kind. It’s a process that is involved with ‘repatenting.’
Many individuals are aware that biotech has developed a seed monopoly largely by patenting genetically modified organisms, but not everyone realizes that Monsanto tried to patent a tomato that had no biotech traits. Now, the European Patent Office (EPO), with help from an international coalition, No Patents on Seeds!, has revoked Monsanto’s fraudulent patent and claim to tomatoes that are naturally resistant to a fungal disease called botryti
Kinsella on Liberty Podcast, Episode 065. I was a guest on The Medical Freedom Report Podcast, with host Michael Ostrolenk, a couple years ago, discussing Patents on Medical Technology and Pharmaceuticals (Feb. 24, 2011). Patents & Copyrights: intellectual property rights or monopoly control of ideas? Why are medical devices protected by patent law while medical procedures are exempt? […]
